No, the CSL product line is too high end and hard to replicate , generic manufacturers selling in the US might have a problem though . But the buying opportunity comes from what the market today will think of Trump's tirade against pharma.
- Forums
- ASX - By Stock
- News: CSL Australia shares end at 20-month high; New Zealand up
No, the CSL product line is too high end and hard to replicate ,...
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$301.81 |
Change
-4.220(1.38%) |
Mkt cap ! $145.8B |
Open | High | Low | Value | Volume |
$302.89 | $302.89 | $299.73 | $34.79M | 115.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28 | $301.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$301.88 | 7 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 74 | 301.760 |
1 | 25 | 301.730 |
2 | 5 | 301.720 |
2 | 113 | 301.710 |
2 | 10 | 301.700 |
Price($) | Vol. | No. |
---|---|---|
301.800 | 16 | 1 |
301.810 | 33 | 2 |
301.860 | 10 | 1 |
301.890 | 6 | 1 |
301.900 | 10 | 1 |
Last trade - 11.50am 04/09/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |